Advisory Board
What The Advisory Board Does
Our advisory board brings together business, academic and regulatory leaders to aid The Biofilms Alliance by guiding the strategic direction and development of the alliance. They advise on the development of the network, stakeholder engagement and commercial exploitation of the results of Biofilm Alliance activities.
The Advisory Board
The Biofilm Alliance advisory board currently consists of
Professor of Pharmaceutical Microbiology at Cardiff University (Wales)
Professor Jean-Yves Maillard
He has 28 years of experience in the field of biocidal product efficacy and microbial resistance, with a particular focus on novel disinfection technologies, sporicides, complex hydrated biofilms, and dry surface biofilms.Over the years, Professor Maillard has received multiple awards, including those for innovation and engagement. He has published more than 200 peer-reviewed articles, 20 book chapters, and 3 books, as well as over 150 refereed conference communications.He is the European lead for the COMplex Biofilms and AMR Transmission project. He is a committee member of the British Standards Institute CH216 Products and Biofilms Working group, of the TC330 committee on antimicrobial hard surfaces, and he leads the TC330 Working Group 1, which assesses the risk of emerging antimicrobial resistance following exposure to antimicrobial hard surfaces. He is a member of the Clean Hospitals expert panel. He is a member of the editorial board for the Journal of Antimicrobial Chemotherapy.
Head (Dean) of the University of Limerick School of Medicine and Foundation
Chair and Director of Research
Professor Colum Dunne BSc (Hons), PhD, MBA, LLM, FRCPath
He is Fellow of the Royal College of Pathologists (London) and a Member of the Royal Irish Academy Life and Health Sciences Committee (RIA). Colum is Trustee and Council Member of the Healthcare Infection Society (London).Colum began third level education at University College Cork (UCC). He held senior research roles at Ireland's National Food Biotechnology Centre, UCC’s Departments of Microbiology and Medicine following a period of research at Michigan State University, USA.Having been General Manager of a cancer research centre developing gene-/chemotherapies and innovative medical devices, Colum joined multinational Glanbia Plc as Director of Research and Board member of the Glanbia Nutritionals group of companies. He is an inventor on multiple patents, and was CEO / Founding Director of SoloPep Ltd, which commercialised infection risk-reduction medical devices.Colum has published >275 peer-reviewed articles regarding intestinal diseases ( Crohn’s disease and ulcerative colitis), microbial colonisation and infection, host response, healthcare associated infections, prevention and ways to mitigate effects.
Senior Consultant: Biocides and Efficacy at Arrow Regulatory Limited
Dr Juncal Caubilla Barron
Juncal earned her PhD in Microbiology from Nottingham Trent University in 2007, subsequently working at the same university in various research positions for two years.In 2009, Juncal joined a major disinfectant manufacturer as the Expert Centre Microbiologist. Over the next seven years, she advanced through positions of increasing responsibility in microbiology, infection prevention, and regulatory affairs. During this time, Juncal developed expertise in microbiology, efficacy testing, diverse cleaning and disinfection product applications, new product development, stakeholder liaison, customer support, marketing claims, and competitor portfolio review.In 2017, she transitioned to regulatory consultancy, starting with TSG Consulting as their Biocides and Efficacy consultant. In 2020, she moved to Arrow Regulatory Limited as a Senior Consultant on Biocides and Efficacy. Her work involved providing general efficacy advice and support on efficacy requirements for various Biocidal Products Regulation (BPR) product types. She gained extensive experience in developing regulatory strategies for biocides, including data gap analysis, intelligent testing strategies, devising product families, and offering tailored regulatory advice. Juncal also possesses experience with the regulatory needs and testing methods for biofilms formed in Product Types (PT) 2, 3, 4, 11, and 12.